黄昊
  • 黄昊

  • 职务:课题组长,特聘研究员,青年千人
  • 电话:+86-755-2603-2321
  • 邮箱: huanghao@pkusz.edu.cn
  • 课题组主页:http://web.pkusz.edu.cn/huanghao/
  • 教育背景及工作经历

    2016-                北京大学深圳研究生院,特聘研究员

    2015-2016        英国剑桥Astex制药公司,高级研究员,基于片段的抗癌药物开发
    2011-2015        加拿大多伦多西奈山医院,博士后,抗癌药物研究
    2006-2011        加拿大卡尔加里大学,博士,生物化学
    2004-2005        加拿大麦克马斯特大学,硕士,化学
    1999-2002        清华大学,硕士,分析化学
    1995-1999        四川大学,学士,生物学
  • 奖项及荣誉

    2015        中组部第十二期国家“千人计划”青年学者

    2014        加拿大卫生与健康研究院(CIHR)博士后基金
    2014        加拿大多伦多TD银行博士后基金
    2008        加拿大阿尔伯特省医学研究基金会(AHFMR)博士生奖学金
  • 研究兴趣

      我们实验室的研究兴趣在于开发化学小分子抗癌药物。我们的研究对象是癌症相关信号通路,特别是泛素化体系,中的重要靶标蛋白。我们利用核磁共振NMR,晶体衍射X-ray等生 物物理方法进行药物小分子片段筛选,并解析药物小分子片段与靶标蛋白的复合物共晶结构。在蛋白质与药物片段复合物晶体结构的基础上,我们利用计算化学等方 法进行合理的药物设计与优化,开发具有高特异性、高亲和力的化学小分子抗癌药物前体。我们的研究课题将基础研究与药物开发直接联系起来,努力实现化学生物 学与结构生物学在抗癌药物开发上的有效结合。在开发抗癌靶向药物的研究中,我们将与本院各个实验室建立紧密的合作,目标是开发出有中国自主知识产权的抗癌 新药。欢迎化学化工,生物学,药学等相关专业的同学,博士后和研究助理与我联系,加入我们的研究团队!      

  • 代表性成果

    发表文章 
    1.  Huang H, Zeqiraj E, Dong B, Jha BK, Duffy NM, Orlicky S, Thevakumaran N, Talukdar M, Pillon MC, Ceccarelli DF, Wan LC, Juang YC, Mao DY, Gaughan C, Brinton MA, Perelygin AA, Kourinov I, Guarné A, Silverman RH, Sicheri F, Dimeric structure of pseudokinase RNase L bound to 2-5A reveals a basis for interferon induced antiviral activity.  Mol. Cell. 2014; 53, 221-34 (Recommended by F1000:http://f1000.com/prime/718246713)
    2. Huang H*, Ceccarelli DF*, Orlicky S*, St-Cyr DJ, Ziemba A, Garg P, Plamondon S, Auer M, Sidhu S, Marinier A, Kleiger G, Tyers M, Sicheri F, E2 enzyme inhibition by stabilization of a low-affinity interface with ubiquitin. Nat. Chem. Biol. 2014 10, 156-63
    3. Fradet-Turcotte A, Canny MD, Escribano-Díaz C, Orthwein A, Leung CC, Huang H, Landry MC, Kitevski-LeBlanc J, Noordermeer SM, Sicheri F, Durocher D. 53BP1 is a reader of the DNA-damage-induced H2A Lys 15 ubiquitin mark. Nature. 2013, 499, 50-54. 
    4. Rivkin E, Almeida SM, Ceccarelli DF, Juang YC, MacLean TA, Srikumar T, Huang H, Dunham WH, Fukumura R, Xie G, Gondo Y, Raught B, Gingras AC, Sicheri F, Cordes SP. The linear ubiquitin-specific deubiquitinase gumby regulates angiogenesis.  Nature. 2013, 498, 318-24
    5. Huang H, Bogstie JN, Vogel HJ, Biophysical and Structural Studies of the Human Calcium- and Integrin-Binding Protein Family: Understanding their Functional Similarities and Differences. Biochem. Cell Biol., 2012, 90, 646-56
    6. Huang H and Vogel HJ, Structural Basis for the Activation of the Cytoplasmic Domain of the Human Platelet Integrin AlphaIIb-beta3 by CIB1. J. Am. Chem. Soc.2012, 134, 3864-72(Highlighted in Science Daily:http://www.sciencedaily.com/releases/2012/03/120319095011.htm)
    7. Huang H, Ishida H, Yamniuk, AP, Vogel HJ, The Solution Structures of Ca2+- CIB1 and Mg2+-CIB1 and their interactions with the Platelet Integrin αIIb Cytoplasmic Domain. J. Biol. Chem., 2011, 286, 17181-92
    8. Huang H, Ishida H, Vogel HJ, The Solution Structure of the Mg2+- form of Soybean Calmodulin Isoform 4 Reveals Unique Features of Plant Calmodulins in Resting Cells. Protein Sci., 2010, 19, 475-85
    9. Huang H, Milojevic J, Melacini G, Analysis and optimization of saturation transfer difference NMR experiments designed to map early self-association events in amyloidogenic peptides. J. Phys. Chem. B., 2008,112, 5795-802
    10. Huang H, Melacini G. High-resolution protein hydration NMR experiments: Probing how protein surfaces interact with water and other non-covalent ligands. Anal. Chim. Acta., 2006, 564, 1-9.

    国际专利
    Tyers M, Sicheri F, Ceccarelli DF, Huang H, et al., Screening methods to identify compounds inhibiting the activity of E2 enzymes by stabilization of non-covalent ubiquitin-E2 complexes and pharmaceutical applications related to E2 inhibitors. Application #: PCT/CA2013/001079;